Brands
Gaurav Tandon brings Limited Edt to India
Mumbai: Limited Edt, the Singapore-based sneaker and lifestyle chain, with a legacy spanning for more than two decades, is poised to cut through the Indian market under the visionary leadership of Gaurav Tandon. With a deep comprehension of market dynamics and consumer behavior, Tandon is all set to lead Limited Edt, into the vibrant Indian market.
Tandon, renowned for his impeccable business acumen and market insights, takes over the reins as the managing director, overseeing all business aspects, bringing with him a wealth of experience from his previous leadership roles as Vice President of Deutsche Post AG and Founder of Amaze Consulting Services and top consulting firms like Aon Hewitt and Mercer.
Limited Edt’s expansion into India comes at an opportune time, with the country’s sneaker and streetwear market projected to reach a revenue of US$2.80 billion by 2024, presenting exciting growth prospects. Reflecting on the brand’s expansion, Mandeep affirms, “India’s dynamic landscape presents limitless opportunities for Limited Edt to thrive. Tandon’s vision for the streetwear and lifestyle industry in India, along with his strategic business management and development skills, aligns perfectly well with my vision for Limited Edt India, that is, to redefine the sneaker culture and what it means to be the ‘only’ sneaker destination in the country.”
Speaking on his new role, he said, “I am thrilled to spearhead Limited Edt’s journey into India’s burgeoning sneaker and streetwear fashion scene. We want to create an experience that is all about authenticity, exclusivity, and exceptional craftsmanship. Our upcoming partnerships are going to celebrate and promote India’s local culture, talent, and design while, of course, catering to the diverse needs of Indian consumers. I am someone who believes in shaping trends, and this opportunity as an M.D. is all about that.”
With his global influence and deep understanding of cultural nuances, Tandon is poised to drive Limited Edt’s success in India. The brand’s partnerships with esteemed names like Adidas Consortium and Asics are just the beginning, showcasing its commitment to delivering exclusive footwear collections.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
